Last updated: 04/22/2020 07:40:10
Minimum Clinically Important Improvement following diclofenac sodium gel 1% in knee and hand osteoarthritis.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Post hoc analyses on the efficacy of diclofenac sodium gel 1% in, vehicle controlled, Knee and Hand Osteoarthritis (Titan Project)
Trial description: The aim of this analysis was to pool data from 3 knee studies and 1 hand study with similar clinical design to investigate the overall efficacy of diclofenac sodium gel 1% in the treatment of knee and hand osteoarthritis after 12 weeks. This post-hoc analysis was planned and conducted after completion of all 4 independent studies.
Primary purpose:
Other
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
To assess minimum Clinically Important Improvement (MCII) Responders Analysis for Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, WOMAC function, WOMAC stiffness and pain on movement (POM)
Timeframe: At Week 1
To assess MCII Responders Analysis for WOMAC pain, WOMAC function, WOMAC stiffness and POM)
Timeframe: At Week 12
To assess MCII Responders Analysis for pain intensity Visual Analogue Scale (VAS), Australian/Canadian Osteoarthritis Hand Index (AUSCAN) total score, AUSCAN pain, AUSCAN stiffness and AUSCAN function
Timeframe: At Week 1
To assess MCII Responders Analysis for pain intensity VAS, AUSCAN total score, AUSCAN pain, AUSCAN stiffness and AUSCAN function
Timeframe: At Week 4
Secondary outcomes:
To assess the effect of Body Mass Index (BMI) on WOMAC pain, WOMAC function, WOMAC stiffness and POM
Timeframe: At Week 12
Interventions:
Enrollment:
1809
Primary completion date:
2019-26-06
Observational study model:
Cohort
Time perspective:
Prospective
Clinical publications:
Not applicable
Medical condition
Osteoarthritis of knee, Pain
Product
diclofenac
Collaborators
Not applicable
Study date(s)
January 2019 to June 2019
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
35 - 92 Years
Accepts healthy volunteers
Yes
- Males and females who are 35 years of age with OA of one or both knees, or ≥ 35 years of age with primary arthritis of hand
- Participants suffering from secondary arthritis, rheumatoid arthritis, and fibromyalgia.
Inclusion and exclusion criteria
Inclusion criteria:
- Males and females who are 35 years of age with OA of one or both knees, or ≥ 35 years of age with primary arthritis of hand
Exclusion criteria:
- Participants suffering from secondary arthritis, rheumatoid arthritis, and fibromyalgia.
Trial location(s)
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
2019-26-06
Actual study completion date
2019-26-06
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website